Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A missense mutation in Muc2 promotes gut microbiome and metabolome-dependent colitis-associated tumorigenesis
Giulio Verna, Stefania De Santis, Bianca N. Islam, Eduardo M. Sommella, Danilo Licastro, Liangliang Zhang, Fabiano De Almeida Celio, Emily N. Miller, Fabrizio Merciai, Vicky Caponigro, Wei Xin, Pietro Campiglia, Theresa T. Pizarro, Marcello Chieppa, Fabio Cominelli
Giulio Verna, Stefania De Santis, Bianca N. Islam, Eduardo M. Sommella, Danilo Licastro, Liangliang Zhang, Fabiano De Almeida Celio, Emily N. Miller, Fabrizio Merciai, Vicky Caponigro, Wei Xin, Pietro Campiglia, Theresa T. Pizarro, Marcello Chieppa, Fabio Cominelli
View: Text | PDF
Research Article Gastroenterology Inflammation

A missense mutation in Muc2 promotes gut microbiome and metabolome-dependent colitis-associated tumorigenesis

  • Text
  • PDF
Abstract

Colitis-associated cancer (CAC) arises from a complex interplay between host and environmental factors. In this report, we investigated the role of the gut microbiome using Winnie mice, an ulcerative colitis–like (UC-like) model with a missense mutation in the Muc2 gene. Upon rederivation from a conventional (CONV) to a specific pathogen–free (SPF) facility, Winnie mice developed severe colitis and, notably, spontaneous CAC that progressively worsened over time. In contrast, CONV Winnie mice showed only mild colitis but no tumorigenesis. By comparison, when re-derived into germ-free (GF) conditions, SPF Winnie mice were protected from colitis and colon tumors, indicating an essential role for the gut microbiome in the development of CAC in these mice. Using shotgun metagenomics, metabolomics, and lipidomics, we identified a distinct proinflammatory microbial and metabolic signature that potentially drives the transition from colitis to CAC. Using either SPF Winnie or WT (Bl/6) donors, fecal microbiota transplantation (FMT) into GF Winnie recipients demonstrated that, while colitis developed regardless of the donor, only FM from SPF Winnie donors resulted in CAC in recipient mice. Our studies present a relevant model of CAC, providing strong evidence that the microbiome plays a key role in its pathogenesis, thus challenging the concept of colon cancer as a strictly nontransmissible disease.

Authors

Giulio Verna, Stefania De Santis, Bianca N. Islam, Eduardo M. Sommella, Danilo Licastro, Liangliang Zhang, Fabiano De Almeida Celio, Emily N. Miller, Fabrizio Merciai, Vicky Caponigro, Wei Xin, Pietro Campiglia, Theresa T. Pizarro, Marcello Chieppa, Fabio Cominelli

×

Figure 3

Microbiome composition differs in tumor-bearing SPF versus CONV Winnie mice, with differential regulation of Gastranaerophilales, Rhodospirillales, Lachnospiraceae AC2044 group, and Alloprevotella.

Options: View larger image (or click on image) Download as PowerPoint
Microbiome composition differs in tumor-bearing SPF versus CONV Winnie m...
(A–E) 16S rRNA-Seq of fecal total microbiota from 20-week-old SPF (n = 12) and CONV (n = 8) Winnie mice. (A) Observed operational taxonomic unit (OTU), (B) Shannon diversity index, and (C) PCA were assessed in the 2 experimental groups. (D) Pie charts for SPF (right) and CONV (left) Winnie stool, indicating percentages of the most abundant genera (>1%). (E) Relative abundance (expressed as a percentage) of significantly represented genera in the stools of 20-week-old SPF (n = 12) and CONV (n = 8) Winnie mice. (F–H) 16S rRNA-Seq of nontumor and tumor-associated microbiota from 20-week-old SPF Winnie mice. (F) PCA with (G) pie charts depicting nontumor mucosa (upper) and tumor-associated mucosa (lower), showing percentages of the most abundant genera (>1%) and the (H) relative abundance (expressed as a percentage) of significantly represented genera in SPF Winnie. Data presented in the dot plots are expressed as the mean ± SEM. n = 12 for each experimental group. *P < 0.05, ***P < 0.0005, and ****P < 0.0001, by unpaired 2-tailed t test or Mann-Whitney U test.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts